SUMMARY Early puberty in 28 children (23 girls, five boys) treated for acute lymphoblastic leukaemia (ALL) at a mean age of 4-0 years (range 1-4-7-8) is described. All but one had received prophylactic cranial irradiation (1800-2400 cGy) and three children had received additional cranial or craniospinal irradiation as treatment for relapse of their leukaemia. Mean age for the onset of puberty was 8.8 (SD 0.8) years in the girls and 9 3 (0.8) years in the boys; this is greater than two standard deviations from the mean for normal girls and boys. Five children (three girls, two boys) had precocious puberty. The onset of puberty occurred at greater than two standard deviations from the mean for normal girls and boys in 14(13%) girls and 4(3%) boys treated at less than eight years of age between 1970 and 1985. In a group of 55 girls treated for ALL who had survived in first remission for six years or more from diagnosis, there was a relation between young age at onset of treatment and early menarche. We suggest that premature activation of the hypothalamic-pituitary-gonadal axis occurs as a consequence of hypothalamic dysfunction due to cranial irradiation. Precocious and premature puberty in children treated for ALL may be an important factor in contributing to short stature.
The outcome for children with acute lymphoblastic leukaemia (ALL) has steadily improved since the introduction of combination chemotherapy and measures to prevent overt leukaemic infiltration of the central nervous system.1 The most common form of prophylaxis to prevent infiltration comprises fractionated cranial irradiation and a course of intrathecal methotrexate. Cranial irradiation commonly causes pituitary dysfunction when given in high doses for treatment of tumours of the central nervous system that are distant from the hypothalamic pituitary region. Growth hormone deficiency,2 delayed puberty,3 4 and precocious puberty5 6 Precocious and premature puberty associated with treatment of acute lymphoblastic leukaemia 1109
Fourteen patients (11 girls, three boys) had computed tomograms taken of the brain by either a Toshiba TCT 60 scanner with hypothalamic pituitary reconstructions or an EMI scanner. Mean timing of the first scan from the onset of prophylactic central nervous system irradiation was 2-75 years (range 0.1-11-0); five patients had brain scans before one year from the onset of central nervous system irradiation. Nine patients had serial computed tomograms taken, up to a maximum of four scans.
Results
Fig 1 shows the age of onset of puberty in the 28 patients compared with data from normal children; three girls and two boys had precocious puberty (signs of sexual maturation occurring before 8 years in girls and 9 years in boys. 19 Mean age for the onset of puberty was 8-8 (SD 0.8) years in the girls and 9-3 (0-8) years in the boys. Mean age for the onset of puberty in these 28 patients was greater than two standard deviations from the mean for normal girls'7 Age (years ) heights equal to or less than the third centile but their growth hormone state and epiphyseal maturation had not been assessed, and no conclusion can be drawn from these data about the effect of early puberty on growth prognosis.
None of the computed tomograms showed evidence of hydrocephalus, and the ventricular size in patients who had serial scans did not change. One girl had diffuse cerebral changes that were probably due to methotrexate encephalopathy. Another girl had an empty sella; this has been associated with irradiation damage.21
Data relating age of onset of treatment of 55 girls with age at menarche are shown in fig 3. The younger the age at diagnosis (equivalent to age at the start of treatement) the earlier menarche occurred (r=0-53, p<0-001).
Discussion
Our data suggest that treatment of ALL is associated with the development of premature puberty, and, in a significant proportion of children, precocious puberty. Our patients retained the harmony of the sequence of acquisition of secondary sexual characteristics and the relation of these to the growth spurt that is characteristic of normal puberty.22 Therefore, premature and precocious puberty in our patients was likely to be central (gonadotrophin dependent) in origin, although we do not have endocrinological data. The onset of pubertal development was related to the age of onset of treatment. This parallels the finding that young children are more susceptible to growth hormone insufficiency after prophylaxis with cranial irradiation in the treatment of ALL. 23 Cranial irradiation has been reported to cause central precocious puberty in both the treatment of brain tumours in doses greater than 3300 cGy and in one girl with ALL when the dose of irradiation was only 2400 cGy6; this girl, however, also received intrathecal methotrexate. In our patients premature puberty was associated with doses of cranial irradiation as low as 1800 cGy. The incidence of early puberty was slightly higher in the group of patients diagnosed between 1970 and 1980. This is likely to reflect the greater proportion of children of adolescent age, but the lower dosage of 1800 cGy of cranial irradiation introduced in 1981 may also have bearing on this observation. Only greater numbers and a longer follow up will elucidate this further. Damage to the hypothalamic-pituitary axis can 0-cause abnormal secretion of gonadotrophin releasing hormone and be associated with either precocious or delayed puberty.3 The change in hypothalamic function that we have seen was probably caused by irradiation rather than intrathecal chemotherapy and like other endocrine effects of irradiation seems to have been delayed. 2 We found no evidence of hydrocephalus occurring as a consequence of cranial irradiation in the regimen that we used.
There was a four fold preponderance of girls with early puberty that was not accounted for by superior survival of girls over boys. In this study, when all criteria for inclusion were met, there were roughly equal numbers of boys and girls. There is a sex difference in the response to gonadotrophin releasing hormone and its analogues that may be relevant to this observation. In delayed puberty induced by pulsatile administration of gonadotrophin releasing hormone girls require lower doses than boys to maintain equivalent progress in sexual maturation. 24 By contrast, in the suppression of central precocious puberty, girls require larger doses of gonadotrophin releasing hormone analogue than boys.25
The growth of children with central precocious puberty is compromised by rapid epiphyseal maturation that ultimately limits growth.'9 It may well be that premature puberty, such as we have described, may cause a similar phenomenon. There are many other factors, however, such as growth hormone insufficiency, which are pertinent to the growth of children with treated ALL especially those who have been retreated after a relapse.2 The impairment in growth caused by growth hormone insufficiency or spinal irradiation, or both, is probably masked by the early growth spurt associated with precocious or premature puberty. The net result would be a relatively normal growth velocity but with rapid advancement in epiphyseal maturation causing a reduction in adult height potential. Without regular anthropometric measurements, including sitting height and accurate assessment of epiphyseal maturation, such an effect on growth could be misinterpreted.
We believe that the recognition of premature sexual development in children with ALL may be important both for psychological and anthropometric reasons. Although cyproterone acetate26 and probably gonadotrophin releasing hormone analogues27 do not affect the final prediction of height of children with central precocious puberty, both agents suppress sexual maturation. We agree with the suggestion of Brauner and Rappaport6 that a combined approach with a gonadotrophin releasing hormone analogue and human growth hormone may therefore provide the best anthropometric response.
Shalet has dicussed the role of endocrine deficiency and spinal growth in the impairment of the growth of children with treated ALL.28 We wish to add to the list premature and precocious puberty as important additional sequelae.
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